| Breast endothelial cell expression patterns -> Monitor Keywords |
|
|
  Breast endothelial cell expression patternsUSPTO Application #: 20070178090Title: Breast endothelial cell expression patterns Abstract: To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future. (end of abstract)
Agent: Banner & Witcoff, Ltd. - Washington, DC, US USPTO Applicaton #: 20070178090 - Class: 424144100 (USPTO) Related Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material, Monoclonal Antibody Or Fragment Thereof (i.e., Produced By Any Cloning Technology), Binds Receptor, Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.) The Patent Description & Claims data below is from USPTO Patent Application 20070178090. Brief Patent Description - Full Patent Description - Patent Application Claims
[0001] This application claims priority to provisional U.S. Application Ser. No. 60/458,960, filed Apr. 1, 2003. TECHNICAL FIELD OF THE INVENTION [0002] This invention is related to the area of angiogenesis and anti-angiogenesis. In particular, it relates to genes which are characteristically expressed in breast tumor endothelial cells. BACKGROUND OF THE INVENTION [0003] To date, global gene expression profiles from endothelial cell-specific populations is limited to normal and tumorigenic colon tissue [St Croix, 2000]. There is a need in the art for analysis of endothelial cells from other tissue, so that diagnostic and therapeutic agents for non-colonic tumors can be developed. SUMMARY OF THE INVENTION [0004] According to one embodiment of the invention a method is provided to aid in diagnosing breast tumors. An expression product (protein or RNA) of at least one gene in a first breast tissue sample suspected of being neoplastic is detected. The at least one gene is selected from the group consisting of hypothetical protein DKFZp434G171; heat shock 70 kDa protein 1A; jagged 1 (Alagille syndrome); cyclin-dependent kinase 3; 6-phosphogluconolactonase; likely homolog of rat and mouse retinoid-inducible serine carboxypeptidase; plasmalemma vesicle associated protein; NADH:ubiquinone oxidoreductase MLRQ subunit homolog; HIF-1 responsive RTP801; ribosomal protein L27; secreted protein, acidic, cysteine-rich (osteonectin); hexokinase 1; ribosomal protein L13a; collagen, type IV, alpha 1; insulin-like growth factor binding protein 7; collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); heat shock 10 kDa protein 1 (chaperonin 10); calcium channel, voltage-dependent, alpha 1H subunit; CD9 antigen (p24); TEM17; TEM13, Thy-1 cell surface antigen; Tax interaction protein 1; dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); hypothetical protein MGC34648; putative translation initiation factor; insulin-like growth factor binding protein 4; matrix metalloproteinase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase); heterogeneous nuclear ribonucleoprotein R; bHLH factor Hes4; collagen, type VI, alpha 2; T-box 2; glyceraldehyde-3-phosphate dehydrogenase; G protein-coupled receptor 4; collagen, type I, alpha 1; ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1); ribosomal protein, large, P1; TEM10, COL1A2 involved in tissue remodeling; heat shock 70 kDa protein 8; KIAA0152 gene product; Ca2+-promoted Ras inactivator; serine/arginine repetitive matrix 2; hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor); benzodiazapine receptor (peripheral); ectonucleoside triphosphate diphosphohydrolase 1; heparan sulfate proteoglycan 2 (perlecan); fibromodulin; hairy/enhancer-of-split related with YRPW motif 1; collagen, type V, alpha 3; hairy/enhancer-of-split related with YRPW motif-like; hypothetical protein MGC2731; amino-terminal enhancer of split; mitogen-activated protein kinase 9; regulator of G-protein signalling 5; prothymosin, alpha (gene sequence 28); tubulin, beta, 2; protease, serine, 23; hypothetical protein FLJ20898; calpain 1, (mu/I) large subunit; interferon, alpha-inducible protein (clone IFI-6-16); ESTs, Weakly similar to T25031 hypothetical protein T20D3.3--Caenorhabditis elegans [C.elegans]; major histocompatibility complex, class I, C; hypoxia up-regulated 1; complement component 4B; prefoldin 2; cytoskeleton-associated protein 1; Rho GTPase activating protein 4; Homo sapiens clone FLC1492 PRO3121 mRNA, complete cds; transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila); ribosomal protein L37; hypothetical protein MGC4677; ESTs, Highly similar to MT1A_HUMAN METALLOTHIONEIN-IA (MT-1A) [H.sapiens]; TEM11, nidogen (enactin); guanine nucleotide binding protein (G protein), gamma 5; matrix Gla protein; heat shock 105 kD; GNAS complex locus; Homo sapiens cDNA FLJ11658 fis, clone HEMBA1004577; H19, imprinted maternally expressed untranslated mRNA; protein tyrosine phosphatase type IVA, member 3; snail homolog 1 (Drosophila); integrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II); tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor); peptidylprolyl isomerase B (cyclophilin B); MARCKS-like protein; FAST kinase; protease, serine, 11 (IGF binding); beta-2-microglobulin; delta sleep inducing peptide, immunoreactor; collagen, type IV, alpha 2; immediate early response 3; cadherin 5, type 2, VE-cadherin (vascular epithelium); RGC32 protein; guanylate cyclase 1, soluble, beta 3; major histocompatibility complex, class I, B; ribonuclease, RNase A family, 1 (pancreatic); collagen, type XVIII, alpha 1; v-jun sarcoma virus 17 oncogene homolog (avian); Homo sapiens mRNA; cDNA DKFZp686G1610 (from clone DKFZp686G1610); nucleolin; lectin, galactoside-binding, soluble, 3 binding protein; Lysosomal-associated multispanning membrane protein-5; ribosomal protein S16; guanine nucleotide binding protein (G protein), gamma 12; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; biglycan; DnaJ (Hsp40) homolog, subfamily B, member 1; tumor rejection antigen (gp96) 1; interferon, alpha-inducible protein (clone IFI-15K); solute carrier family 21 (prostaglandin transporter), member 2; CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); serum/glucocorticoid regulated kinase; mitogen-activated protein kinase; receptor (calcitonin) activity modifying protein 3; sema domain, immunoglobulin domain (Ig); benzodiazapine receptor (peripheral)--mitochondrial; C1domain-containing phosphatase & tensin-like; and Notch homolog 3 (Drosophila). Expression of the at least one gene in the first breast tissue sample is compared to expression of the at least one gene in a second breast tissue sample which is normal. Increased expression of the at least one gene in the first breast endothelial tissue sample relative to the second tissue sample identifies the first breast tissue sample as likely to be neoplastic. [0005] According to another embodiment of the invention a method is provided of treating a breast tumor. Cells of the breast tumor are contacted with an antibody. The antibody specifically binds to an extracellular epitope of a protein selected from the group consisting of benzodiazapine receptor (peripheral); cadherin 5, type 2, VE-cadherin (vascular epithelium); calcium channel, voltage-dependent, alpha 1H subunit; CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); CD9 antigen (p24); dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); ectonucleoside triphosphate diphosphohydrolase 1; G protein-coupled receptor 4; hypothetical protein FLJ20898; hypoxia up-regulated 1; immediate early response 3; interferon, alpha-inducible protein (clone IFI-6-16); jagged 1 (Alagille syndrome); KIAA0152 gene product; Lysosomal-associated multispanning membrane protein-5; major histocompatibility complex, class I, B; major histocompatibility complex, class I, C; NADH:ubiquinone oxidoreductase MLRQ subunit homolog; Notch homolog 3 (Drosophila); plasmalemma vesicle associated protein; solute carrier family 21 (prostaglandin transporter), member 2; TEM13, Thy-1 cell surface antigen; receptor (calcitonin) activity modifying protein 3; sema domain, immunoglobulin domain (Ig); benzodiazapine receptor (peripheral)--mitochondrial; and TEM17. Immune destruction of cells of the breast tumor is thereby triggered. [0006] According to still another embodiment of the invention a method is provided for identifying a test compound as a potential anti-cancer or anti-breast tumor drug. A test compound is contacted with a cell which expresses at least one gene selected from the group consisting of: hypothetical protein DKFZp434G171; heat shock 70 kDa protein 1A; jagged 1 (Alagille syndrome); cyclin-dependent kinase 3; 6-phosphogluconolactonase; likely homolog of rat and mouse retinoid-inducible serine carboxypeptidase; plasmalemma vesicle associated protein; NADH:ubiquinone oxidoreductase MLRQ subunit homolog; HIF-1 responsive RTP801; ribosomal protein L27; secreted protein, acidic, cysteine-rich (osteonectin); hexokinase 1; ribosomal protein L13a; collagen, type IV, alpha 1; insulin-like growth factor binding protein 7; collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); heat shock 10 kDa protein 1 (chaperonin 10); calcium channel, voltage-dependent, alpha 1H subunit; CD9 antigen (p24); TEM17; TEM13, Thy-1 cell surface antigen; Tax interaction protein 1; dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); hypothetical protein MGC34648; putative translation initiation factor; insulin-like growth factor binding protein 4; matrix metalloproteinase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase); heterogeneous nuclear ribonucleoprotein R; bHLH factor Hes4; collagen, type VI, alpha 2; T-box 2; glyceraldehyde-3-phosphate dehydrogenase; G protein-coupled receptor 4; collagen, type I, alpha 1; ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1); ribosomal protein, large, P1; TEM10, COL1A2 involved in tissue remodeling; heat shock 70 kDa protein 8; KIAA0152 gene product; Ca2+-promoted Ras inactivator; serine/arginine repetitive matrix 2; hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor); benzodiazapine receptor (peripheral); ectonucleoside triphosphate diphosphohydrolase 1; heparan sulfate proteoglycan 2 (perlecan); fibromodulin; hairy/enhancer-of-split related with YRPW motif 1; collagen, type V, alpha 3; hairy/enhancer-of-split related with YRPW motif-like; hypothetical protein MGC2731; amino-terminal enhancer of split; mitogen-activated protein kinase 9; regulator of G-protein signalling 5; prothymosin, alpha (gene sequence 28); tubulin, beta, 2; protease, serine, 23; hypothetical protein FLJ20898; calpain 1, (mu/I) large subunit; interferon, alpha-inducible protein (clone IFI-6-16); ESTs, Weakly similar to T25031 hypothetical protein T20D3.3--Caenorhabditis elegans [C.elegans ]; major histocompatibility complex, class I, C; hypoxia up-regulated 1; complement component 4B; prefoldin 2; cytoskeleton-associated protein 1; Rho GTPase activating protein 4; Homo sapiens clone FLC1492 PRO3121 mRNA, complete cds; transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila); ribosomal protein L37; hypothetical protein MGC4677; ESTs, Highly similar to MT1A_HUMAN METALLOTHIONEIN-IA (MT-1A) [H.sapiens]; TEM11, nidogen (enactin); guanine nucleotide binding protein (G protein), gamma 5; matrix Gla protein; heat shock 105 kD; GNAS complex locus; Homo sapiens cDNA FLJ11658 fis, clone HEMBA1004577; H19, imprinted maternally expressed untranslated mRNA; protein tyrosine phosphatase type IVA, member 3; snail homolog 1 (Drosophila); integrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II); tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor); peptidylprolyl isomerase B (cyclophilin B); MARCKS-like protein; FAST kinase; protease, serine, 11 (IGF binding); beta-2-microglobulin; delta sleep inducing peptide, immunoreactor; collagen, type IV, alpha 2; immediate early response 3; cadherin 5, type 2, VE-cadherin (vascular epithelium); RGC32 protein; guanylate cyclase 1, soluble, beta 3; major histocompatibility complex, class I, B; ribonuclease, RNase A family, 1 (pancreatic); collagen, type XVIII, alpha 1; v-jun sarcoma virus 17 oncogene homolog (avian); Homo sapiens mRNA; cDNA DKFZp686G1610 (from clone DKFZp686G1610); nucleolin; lectin, galactoside-binding, soluble, 3 binding protein; Lysosomal-associated multispanning membrane protein-5; ribosomal protein S16; guanine nucleotide binding protein (G protein), gamma 12; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; biglycan; DnaJ (Hsp40) homolog, subfamily B, member 1; tumor rejection antigen (gp96) 1; interferon, alpha-inducible protein (clone IFI-15K); solute carrier family 21 (prostaglandin transporter), member 2; CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); serum/glucocorticoid regulated kinase; mitogen-activated protein kinase; receptor (calcitonin) activity modifying protein 3; sema domain, immunoglobulin domain (Ig); benzodiazapine receptor (peripheral)--mitochondrial; C1 domain-containing phosphatase & tensin-like; and Notch homolog 3 (Drosophila). An expression product of the at least one gene is monitored. The test compound is identified as a potential anti-cancer drug if it decreases the expression of the at least one gene. [0007] Still another embodiment of the invention is a method to induce an immune response to a breast tumor. A protein or nucleic acid encoding a protein is administered to a mammal, preferably a human. The protein is selected from the group consisting of: hypothetical protein DKFZp434G171; heat shock 70 kDa protein 1A; jagged 1 (Alagille syndrome); cyclin-dependent kinase 3; 6-phosphogluconolactonase; likely homolog of rat and mouse retinoid-inducible serine carboxypeptidase; plasmalemma vesicle associated protein; NADH:ubiquinone oxidoreductase MLRQ subunit homolog; HIF-1 responsive RTP801; ribosomal protein L27; secreted protein, acidic, cysteine-rich (osteonectin); hexokinase 1; ribosomal protein L13a; collagen, type IV, alpha 1; insulin-like growth factor binding protein 7; collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); heat shock 10 kDa protein 1 (chaperonin 10); calcium channel, voltage-dependent, alpha 1H subunit; CD9 antigen (p24); TEM17; TEM13, Thy-1 cell surface antigen; Tax interaction protein 1; dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); hypothetical protein MGC34648; putative translation initiation factor; insulin-like growth factor binding protein 4; matrix metalloproteinase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase); heterogeneous nuclear ribonucleoprotein R; bHLH factor Hes4; collagen, type VI, alpha 2; T-box 2; glyceraldehyde-3-phosphate dehydrogenase; G protein-coupled receptor 4; collagen, type I, alpha 1; ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1); ribosomal protein, large, P1; TEM10, COL1A2 involved in tissue remodeling; heat shock 70 kDa protein 8; KIAA0152 gene product; Ca2+-promoted Ras inactivator; serine/arginine repetitive matrix 2; hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor); benzodiazapine receptor (peripheral); ectonucleoside triphosphate diphosphohydrolase 1; heparan sulfate proteoglycan 2 (perlecan); fibromodulin; hairy/enhancer-of-split related with YRPW motif 1; collagen, type V, alpha 3; hairy/enhancer-of-split related with YRPW motif-like; hypothetical protein MGC2731; amino-terminal enhancer of split; mitogen-activated protein kinase 9; regulator of G-protein signalling 5; prothymosin, alpha (gene sequence 28); tubulin, beta, 2; protease, serine, 23; hypothetical protein FLJ20898; calpain 1, (mu/I) large subunit; interferon, alpha-inducible protein (clone IFI-6-16); ESTs, Weakly similar to T25031 hypothetical protein T20D3.3 --Caenorhabditis elegans [C.elegans]; major histocompatibility complex, class I, C; hypoxia up-regulated 1; complement component 4B; prefoldin 2; cytoskeleton-associated protein 1; Rho GTPase activating protein 4; Homo sapiens clone FLC1492 PRO3121 mRNA, complete cds; transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila); ribosomal protein L37; hypothetical protein MGC4677; ESTs, Highly similar to MT1A_HUMAN METALLOTHIONEIN-IA (MT-1A) [H.sapiens]; TEM11, nidogen (enactin); guanine nucleotide binding protein (G protein), gamma 5; matrix Gla protein; heat shock 105 kD; GNAS complex locus; Homo sapiens cDNA FLJ11658 fis, clone HEMBA1004577; H19, imprinted maternally expressed untranslated mRNA; protein tyrosine phosphatase type IVA, member 3; snail homolog 1 (Drosophila); integrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II); tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor); peptidylprolyl isomerase B (cyclophilin B); MARCKS-like protein; FAST kinase; protease, serine, 11 (IGF binding); beta-2-microglobulin; delta sleep inducing peptide, immunoreactor; collagen, type IV, alpha 2; immediate early response 3; cadherin 5, type 2, VE-cadherin (vascular epithelium); RGC32 protein; guanylate cyclase 1, soluble, beta 3; major histocompatibility complex, class I, B; ribonuclease, RNase A family, 1 (pancreatic); collagen, type XVIII, alpha 1; v-jun sarcoma virus 17 oncogene homolog (avian); Homo sapiens mRNA; cDNA DKFZp686G1610 (from clone DKFZp686G1610); nucleolin; lectin, galactoside-binding, soluble, 3 binding protein; Lysosomal-associated multispanning membrane protein-5; ribosomal protein S16; guanine nucleotide binding protein (G protein), gamma 12; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; biglycan; DnaJ (Hsp40) homolog, subfamily B, member 1; tumor rejection antigen (gp96) 1; interferon, alpha-inducible protein (clone IFI-15K); solute carrier family 21 (prostaglandin transporter), member 2; CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); serum/glucocorticoid regulated kinase; mitogen-activated protein kinase; receptor (calcitonin) activity modifying protein 3; sema domain, immunoglobulin domain (Ig); benzodiazapine receptor (peripheral)--mitochondrial; C1 domain-containing phosphatase & tensin-like; and Notch homolog 3 (Drosophila). An immune response to the protein is thereby induced. [0008] The present invention thus provides the art with methods of diagnosing and treating breast tumors. DETAILED DESCRIPTION OF THE INVENTION [0009] Using SAGE (Serial Analysis of Gene Expression) profiling, the present inventors were able to identify previously unrecognized, angiogenesis-specific markers that discriminate between non-proliferative and pathologic endothelial cells. In addition, a set of previously identified angiogenesis-specific markers from other tumor types (colon and/or brain) were found to be expressed in breast tumor endothelium as well. We identified 111 human genes that were expressed at significantly higher levels in breast tumor endothelium than in normal breast endothelium. See Table 1. Additional such genes which can be used similarly to the 11 human genes are shown in Table 2. We have named these markers BEMs breast tumor endothelial markers). BEMs that are expressed in both colon and breast tumor epithelium are identified in Table 3. BEMs that are expressed in both brain and breast tumor epithelium are identified in Table 4. BEMs that are expressed in each of brain, colon, and breast tumor epithelium are identified in Table 5. TABLE-US-00001 TABLE 1 111 Breast Markers Unigene ID Function OMIMID Protein Hs.8728 hypothetical protein CAB61365 DKFZp434G171 Hs.8997 heat shock 70 kDa protein 1A 140550 NP_005336 Hs.91143 jagged 1 (Alagille syndrome) 601920 NP_000205 Hs.100009 cyclin-dependent kinase 3 123828 Hs.100071 6-phosphogluconolactonase 604951 NP_036220 Hs.106747 likely homolog of rat and NP_067639 mouse retinoid-inducible serine carboxypeptidase Hs.107125 plasmalemma vesicle NP_112600 associated protein Hs.110024 NADH: ubiquinone NP_064527 oxidoreductase MLRQ subunit homolog Hs.111244 HIF-1 responsive RTP801 NP_061931 Hs.111611 ribosomal protein L27 607526 NP_000979 Hs.111779 secreted protein, acidic, 182120 NP_003109 cysteine-rich (osteonectin) Hs.118625 hexokinase 1 142600 NP_277035 Hs.119122 ribosomal protein L13a Hs.119129 collagen, type IV, alpha 1 120130 NP_001836 Hs.119206 insulin-like growth factor 602867 NP_001544 binding protein 7 Hs.119571 collagen, type III, alpha 1 120180 NP_000081 (Ehlers-Danlos syndrome type IV, autosomal dominant) Hs.1197 heat shock 10 kDa protein 1 600141 NP_002148 (chaperonin 10) Hs.122359 calcium channel, voltage- NP_066921 dependent, alpha 1H subunit Hs.1244 CD9 antigen (p24) 143030 NP_001760 Hs.125036 TEM17 606826 NP_065138 Hs.125359 TEM13, Thy-1 cell surface 188230 NP_006279 antigen Hs.12956 Tax interaction protein 1 NP_055419 Hs.143897 dysferlin, limb girdle 603009 NP_003485 muscular dystrophy 2B (autosomal recessive) Hs.146360 hypothetical protein MGC34648 NP_689873 Hs.150580 putative translation NP_005792 initiation factor Hs.1516 insulin-like growth factor 146733 NP_001543 binding protein 4 Hs.151738 matrix metalloproteinase 9 120361 NP_004985 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) Hs.15265 heterogeneous nuclear 607201 NP_005817 ribonucleoprotein R Hs.154029 bHLH factor Hes4 NP_066993 Hs.159263 collagen, type VI, alpha 2 120240 NP_001840 Hs.168357 T-box 2 600747 NP_005985 Hs.169476 glyceraldehyde-3-phosphate 138400 NP_002037 dehydrogenase Hs.17170 G protein-coupled receptor 4 600551 NP_005273 Hs.172928 collagen, type I, alpha 1 120150 NP_000079 Hs.173737 ras-related C3 botulinum 602048 toxin substrate 1 (rho family, small GTP binding protein Rac1) Hs.177592 ribosomal protein, large, P1 180520 Hs.179573 TEM10, COL1A2 involved in 120160 NP_000080 tissue remodeling Hs.180414 heat shock 70 kDa protein 8 600816 NP_006588 Hs.181418 KIAA0152 gene product NP_055545 Hs.184367 Ca2+-promoted Ras BAA25464 inactivator Hs.197114 serine/arginine repetitive 606032 NP_057417 matrix 2 Hs.197540 hypoxia-inducible factor 1, 603348 NP_001521 alpha subunit (basic helix- loop-helix transcription factor) Hs.202 benzodiazapine receptor 109610 NP_000705 (peripheral) Hs.205353 ectonucleoside triphosphate 601752 NP_001767 diphosphohydrolase 1 Hs.211573 heparan sulfate proteoglycan 142461 NP_005520 2 (perlecan) Hs.230 Fibromodulin 600245 NP_002014 Hs.234434 hairy/enhancer-of-split 602953 NP_036390 related with YRPW motif 1 Hs.235368 collagen, type V, alpha 3 120216 NP_056534 Hs.23823 hairy/enhancer-of-split NP_055386 related with YRPW motif-like Hs.240170 hypothetical protein MGC2731 NP_076973 Hs.244 amino-terminal enhancer of 600188 split Hs.246857 mitogen-activated protein 602896 NP_620708 kinase 9 Hs.24950 regulator of G-protein 603276 NP_003608 signalling 5 Hs.250655 prothymosin, alpha (gene 188390 NP_002814 sequence 28) Hs.251653 tubulin, beta, 2 602660 NP_006079 Hs.25338 protease, serine, 23 Hs.25549 hypothetical protein FLJ20898 NP_078876 Hs.2575 calpain 1, (mu/l) large 114220 NP_005177 subunit Hs.265827 interferon, alpha-inducible 147572 NP_075011 protein (clone IFI-6-16) Hs.267200 ESTs, Weakly similar to T25031 hypothetical protein T20D3.3 - Caenorhabditis elegans [C. elegans] Hs.277477 major histocompatibility 142840 NP_002108 complex, class I, C Hs.277704 hypoxia up-regulated 1 601746 NP_006380 Hs.278625 complement component 4B 120820 NP_000583 Hs.298229 prefoldin 2 NP_036526 Hs.31053 cytoskeleton-associated 601303 NP_001272 protein 1 Hs.3109 Rho GTPase activating 300023 NP_001657 protein 4 Hs.327412 Homo sapiens clone FLC1492 PRO3121 mRNA, complete cds Hs.332173 transducin-like enhancer of 601041 NP_003251 split 2 (E(sp1) homolog, Drosophila) Hs.337445 ribosomal protein L37 604181 NP_000988 Hs.337986 hypothetical protein MGC4677 NP_443103 Hs.353882 ESTs, Highly similar to MT1A_HUMAN METALLOTHIONEIN-IA (MT-1A) [H. sapiens] Hs.356624 TEM11, nidogen (enactin) 131390 NP_002499 Hs.356668 guanine nucleotide binding 600874 NP_005265 protein (G protein), gamma 5 Hs.365706 matrix Gla protein 154870 NP_000891 Hs.36927 heat shock 105 Kd NP_006635 Hs.374523 GNAS complex locus 139320 NP_536350 Hs.380824 Homo sapiens cDNA FLJ11658 fis, clone HEMBA1004577 Hs.406410 H19, imprinted maternally 103280 BAB71280 expressed untranslated mRNA Hs.43666 protein tyrosine phosphatase 606449 NP_116000 type IVA, member 3 Hs.48029 snail homolog 1 (Drosophila) 604238 NP_005976 Hs.49215 integrin-binding sialoprotein 147563 NP_004958 (bone sialoprotein, bone sialoprotein II) Hs.5831 tissue inhibitor of 305370 NP_003245 metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) Hs.699 peptidylprolyl isomerase B 123841 NP_000933 (cyclophilin B) Hs.75061 MARCKS-like protein 602940 NP_075385 Hs.75087 FAST kinase 606965 NP_079372 Hs.75111 protease, serine, 11 (IGF 602194 NP_002766 binding) Hs.75415 beta-2-microglobulin 109700 NP_004039 Hs.75450 delta sleep inducing peptide, 602960 immunoreactor Hs.75617 collagen, type IV, alpha 2 120090 NP_001837 Hs.76095 immediate early response 3 602996 NP_434702 Hs.76206 cadherin 5, type 2, VE-cadherin 601120 NP_001786 (vascular epithelium) Hs.76640 RGC32 protein Hs.77890 guanylate cyclase 1, soluble, 139397 NP_000848 beta 3 Hs.77961 major histocompatibility 142830 NP_005505 complex, class I, B Hs.78224 ribonuclease, RNase A family, 180440 AAH05324 1 (pancreatic) Hs.78409 collagen, type XVIII, alpha 1 120328 NP_085059 Hs.78465 v-jun sarcoma virus 17 165160 NP_002219 oncogene homolog (avian) Hs.7869 Homo sapiens mRNA; cDNA DKFZp686G1610 (from clone DKFZp686G1610) Hs.79110 Nucleolin 164035 NP_005372 Hs.79339 lectin, galactoside-binding, 600626 NP_005558 soluble, 3 binding protein Hs.79356 Lysosomal-associated 601476 NP_006753 multispanning membrane protein-5 Hs.80617 ribosomal protein S16 603675 Hs.8107 guanine nucleotide binding protein (G protein), gamma 12 Hs.82085 serine (or cysteine) 173360 NP_000593 proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 Hs.821 Biglycan 301870 NP_001702 Hs.82646 DnaJ (Hsp40) homolog, 604572 NP_006136 subfamily B, member 1 Hs.82689 tumor rejection antigen 191175 NP_003290 (gp96) 1 Hs.833 interferon, alpha-inducible 147571 NP_005092 protein (clone IFI-15K) Hs.83974 solute carrier family 21 601460 NP_005621 (prostaglandin transporter), member 2 Hs.84298 CD74 antigen (invariant 142790 NP_004346 polypeptide of major histocompatibility complex, class II antigen-associated) Hs.8546 Notch homolog 3 (Drosophila) 600276 NP_000426 [0010] TABLE-US-00002 TABLE 2 Additional Tumor Endothelial Markers in Breast Unigene ID Function OMIMID Protein Hs.296323 serum/glucocorticoid regulated 602958 NP_005618 kinase Hs.246857 mitogen-activated protein 602896 NP_620708 kinase Hs.25691 receptor (calcitonin) activity 605155 NP_005847 modifying protein 3 Hs.9598 sema domain, immunoglobulin -- BAB21836 domain (Ig) Hs.202 benzodiazapine receptor 109610 NP_000715 (peripheral) - mitochondrial Hs.6147 C1 domain-containing -- NP_056134 phosphatase & tensin-like [0011] TABLE-US-00003 TABLE 3 Markers in Colon and Breast Tumor Epithelium Unigene ID Function OMIMID Protein Hs.8997 heat shock 70 kDa protein 1A 140550 NP_005336 Hs.110024 NADH: ubiquinone NP_064527 oxidoreductase MLRQ subunit homolog Hs.111779 secreted protein, acidic, 182120 NP_003109 cysteine-rich (osteonectin) Hs.119129 collagen, type IV, alpha 1 120130 NP_001836 Hs.119206 insulin-like growth factor 602867 NP_001544 binding protein 7 Hs.119571 collagen, type III, alpha 1 120180 NP_000081 (Ehlers-Danlos syndrome type IV, autosomal dominant) Hs.1197 heat shock 10 kDa protein 1 600141 NP_002148 (chaperonin 10) Hs.125036 TEM17 606826 NP_065138 Hs.125359 TEM13, Thy-1 cell surface 188230 NP_006279 antigen Hs.151738 matrix metalloproteinase 9 120361 NP_004985 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) Hs.159263 collagen, type VI, alpha 2 120240 NP_001840 Hs.168357 T-box 2 600747 NP_005985 Hs.172928 collagen, type I, alpha 1 120150 NP_000079 Hs.179573 TEM10, COL1A2 involved in 120160 NP_000080 tissue remodeling Hs.230 Fibromodulin 600245 NP_002014 Hs.23823 hairy/enhancer-of-split NP_055386 related with YRPW motif-like Hs.24950 regulator of G-protein 603276 NP_003608 signalling 5 Hs.265827 interferon, alpha-inducible 147572 NP_075011 protein (clone IFI-6-16) Hs.327412 Homo sapiens clone FLC1492 PRO3121 mRNA, complete cds Hs.337986 hypothetical protein NP_443103 MGC4677 Hs.356624 TEM11, nidogen (enactin) 131390 NP_002499 Hs.36927 heat shock 105 kD NP_006635 Hs.43666 protein tyrosine phosphatase 606449 NP_116000 type IVA, member 3 Hs.5831 tissue inhibitor of 305370 NP_003245 metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) Hs.699 peptidylprolyl isomerase B 123841 NP_000933 (cyclophilin B) Hs.75617 collagen, type IV, alpha 2 120090 NP_001837 Hs.77890 guanylate cyclase 1, 139397 NP_000848 soluble, beta 3 Hs.78409 collagen, type XVIII, 120328 NP_085059 alpha 1 Hs.78465 v-jun sarcoma virus 17 165160 NP_002219 oncogene homolog (avian) Hs.821 Biglycan 301870 NP_001702 Hs.82646 DnaJ (Hsp40) homolog, 604572 NP_006136 subfamily B, member 1 Hs.8546 Notch homolog 3 (Drosophila) 600276 NP_000426 [0012] TABLE-US-00004 TABLE 4 Markers in Brain and Breast Tumor Epithelium Unigene ID Function OMIMID Protein Hs.107125 plasmalemma vesicle associated NP_112600 protein Hs.111611 ribosomal protein L27 607526 NP_000979 Hs.111779 Secreted protein, acidic, 182120 NP_003109 cysteine-rich (osteonectin) Hs.119129 Collagen, type IV, alpha 1 120130 NP_001836 Hs.119571 Collagen, type III, alpha 1 120180 NP_000081 (Ehlers-Danlos syndrome type IV, autosomal dominant) Hs.125359 TEM13, Thy-1 cell surface 188230 NP_006279 antigen Hs.143897 Dysferlin, limb girdle 603009 NP_003485 muscular dystrophy 2B (autosomal recessive) Hs.151738 matrix metalloproteinase 9 120361 NP_004985 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) Hs.159263 Collagen, type VI, alpha 2 120240 NP_001840 Hs.172928 Collagen, type I, alpha 1 120150 NP_000079 Hs.179573 TEM10, COL1A2 involved in 120160 NP_000080 tissue remodeling Hs.211573 Heparan sulfate proteoglycan 2 142461 NP_005520 (perlecan) Hs.277477 major histocompatibility 142840 NP_002108 complex, class I, C Hs.327412 Homo sapiens clone FLC1492 PRO3121 mRNA, complete cds Hs.332173 transducin-like enhancer of 601041 NP_003251 split 2 (E(sp1) homolog, Drosophila) Hs.337986 hypothetical protein MGC4677 NP_443103 Hs.365706 matrix Gla protein 154870 NP_000891 Hs.75061 MARCKS-like protein 602940 NP_075385 Hs.75111 Protease, serine, 11 (IGF 602194 NP_002766 binding) Hs.75617 collagen, type IV, alpha 2 120090 NP_001837 Hs.77961 major histocompatibility 142830 NP_005505 complex, class I, B Hs.79356 Lysosomal-associated 601476 NP_006753 multispanning membrane protein-5 Hs.82085 serine (or cysteine) 173360 NP_000593 proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 Hs.821 Biglycan 301870 NP_001702 [0013] TABLE-US-00005 TABLE 5 Breast, Brain, and Colon Tumor Endothelial Markers Unigene ID Function OMIMID Protein Hs.111779 secreted protein, acidic, 182120 NP_003109 cysteine-rich (osteonectin) Hs.119129 collagen, type IV, alpha 1 120130 NP_001836 Hs.119571 collagen, type III, alpha 1 120180 NP_000081 (Ehlers-Danlos syndrome type IV, autosomal dominant) Hs.125359 TEM13, Thy-1 cell surface 188230 NP_006279 antigen Hs.151738 matrix metalloproteinase 9 120361 NP_004985 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) Hs.159263 collagen, type VI, alpha 2 120240 NP_001840 Hs.172928 collagen, type I, alpha 1 120150 NP_000079 Hs.179573 TEM10, COL1A2 involved in 120160 NP_000080 tissue remodeling Hs.327412 Homo sapiens clone FLC1492 PRO3121 mRNA, complete cds Hs.337986 hypothetical protein NP_443103 MGC4677 Hs.75617 collagen, type IV, alpha 2 120090 NP_001837 Hs.821 biglycan 301870 NP_001702 [0014] Endothelial cells (ECs) represent only a minor fraction of the total cells within normal or tumor tissues, and only those EC transcripts expressed at the highest levels would be expected to be represented in libraries constructed from unfractionated tissues. The genes described in the current study should therefore provide a valuable resource for basic and clinical studies of human breast angiogenesis in the future. [0015] Isolated and purified nucleic acids, according to the present invention are those which are not linked to those genes to which they are linked in the human genome. Moreover, they are not present in a mixture such as a library containing a multitude of distinct sequences from distinct genes. They may be, however, linked to other genes such as vector sequences or sequences of other genes to which they are not naturally adjacent. [0016] The nucleic acids may represent either the sense or the anti-sense strand. Nucleic acids and proteins although disclosed herein with sequence particularity, may be derived from a single individual. Allelic variants which occur in the population of humans are included within the scope of such nucleic acids and proteins. Those of skill in the art are well able to identify allelic variants as being the same gene or protein. Given a nucleic acid, one of ordinary skill in the art can readily determine an open reading frame present, and consequently the sequence of a polypeptide encoded by the open reading frame and, using techniques well known in the art, express such protein in a suitable host. Proteins comprising such polypeptides can be the naturally occurring proteins, fusion proteins comprising exogenous sequences from other genes from humans or other species, epitope tagged polypeptides, etc. Isolated and purified proteins are not in a cell, and are separated from the normal cellular constituents, such as nucleic acids, lipids, etc. Typically the protein is purified to such an extent that it comprises the predominant species of protein in the composition, such as greater than 50, 60 70, 80, 90, or even 95% of the proteins present. [0017] Using the proteins according to the invention, one of ordinary skill in the art can readily generate antibodies which specifically bind to the proteins. Such antibodies can be monoclonal or polyclonal. They can be chimeric, humanized, or totally human. Any functional fragment or derivative of an antibody can be used including Fab, Fab', Fab2, Fab'2, and single chain variable regions. So long as the fragment or derivative retains specificity of binding for the endothelial marker protein it can be used. Antibodies can be tested for specificity of binding by comparing binding to appropriate antigen to binding to irrelevant antigen or antigen mixture under a given set of conditions. If the antibody binds to the appropriate antigen at least 2, 5, 7, and preferably 10 times more than to irrelevant antigen or antigen mixture then it is considered to be specific. [0018] Techniques for making such partially to fully human antibodies are known in the art and any such techniques can be used. According to one particularly preferred embodiment, fully human antibody sequences are made in a transgenic mouse which has been engineered to express human heavy and light chain antibody genes. Multiple strains of such transgenic mice have been made which can produce different classes of antibodies. B cells from transgenic mice which are producing a desirable antibody can be fused to make hybridoma cell lines for continuous production of the desired antibody. See for example, Nina D. Russel, Jose R. F. Corvalan, Michael L. Gallo, C. Geoffrey Davis, Liise-Anne Pirofski. Production of Protective Human Antipneumococcal Antibodies by Transgenic Mice with Human Immunoglobulin Loci Infection and Immunity April 2000, p. 1820-1826; Michael L. Gallo, Vladimir E. Ivanov, Aya Jakobovits, and C. Geoffrey Davis. The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans European Journal of Immunology 30: 534-540, 2000; Larry L. Green. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies Journal of Immunological Methods 231 11-23, 1999; Yang X-D, Corvalan J R F, Wang P, Roy C M-N and Davis C G. Fully Human Anti-interleukin-8 Monoclonal Antibodies: Potential Therapeutics for the Treatment of Inflammatory Disease States. Journal of Leukocyte Biology Vol. 66, pp401-410 (1999); Yang X-D, Jia X-C, Corvalan J R F, Wang P, C G Davis and Jakobovits A. Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy. Cancer Research Vol. 59, Number 6, pp1236-1243 (1999); Jakobovits A. Production and selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci. Advanced Drug Delivery Reviews Vol. 31, pp: 33-42 (1998); Green L and Jakobovits A. Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes. J. Exp. Med. Vol. 188, Number 3, pp: 483-495 (1998); Jakobovits A. The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice. Exp. Opin. Invest. Drugs Vol. 7(4), pp: 607-614 (1998); Tsuda H, Maynard-Currie K, Reid L, Yoshida T, Edamura K, Maeda N, Smithies O, Jakobovits A. Inactivation of Mouse HPRT locus by a 203-bp retrotransposon insertion and a 55-kb gene-targeted deletion: establishment of new HPRT-Deficient mouse embryonic sBEM cell lines. Genomics Vol. 42, pp: 413-421 (1997); Sherman-Gold, R. Monoclonal Antibodies: The Evolution from '80s Magic Bullets To Mature, Mainstream Applications as Clinical Therapeutics. Genetic Engineering News Vol. 17, Number 14 (August 1997); Mendez M, Green L, Corvalan J, Jia X-C, Maynard-Currie C, Yang X-d, Gallo M, Louie D, Lee D, Erickson K, Luna J, Roy C, Abderrahim H, Kirschenbaum F, Noguchi M, Smith D, Fukushima A, Hales J, Finer M, Davis C, Zsebo K, Jakobovits A. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nature Genetics Vol. 15, pp: 146-156 (1997); Jakobovits A. Mice engineered with human immunoglobulin YACs: A new technology for production of fully human antibodies for autoimmunity therapy. Weir's Handbook of Experimental Immunology, The Integrated Immune System Vol. IV, pp: 194.1-194.7 (1996); Jakobovits A. Production of fully human antibodies by transgenic mice. Current Opinion in Biotechnology Vol. 6, No. 5, pp: 561-566 (1995); Mendez M, Abderrahim H, Noguchi M, David N, Hardy M, Green L, Tsuda H, Yoast S, Maynard-Currie C, Garza D, BEMmill R, Jakobovits A, Klapholz S. Analysis of the structural integrity of YACs comprising human immunoglobulin genes in yeast and in embryonic sBEM cells. Genomics Vol. 26, pp: 294-307 (1995); Jakobovits A. YAC Vectors: Humanizing the mouse genome. Current Biology Vol. 4, No. 8, pp: 761-763 (1994); Arbones M, Ord D, Ley K, Ratech H, Maynard-Curry K, Otten G, Capon D, Tedder T. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity Vol. 1, No. 4, pp: 247-260 (1994); Green L, Hardy M, Maynard-Curry K, Tsuda H, Louie D, Mendez M, Abderrahim H, Noguchi M, Smith D, Zeng Y, et. al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nature Genetics Vol. 7, No. 1, pp: 13-21 (1994); Jakobovits A, Moore A, Green L, Vergara G, Maynard-Curry K, Austin H, Klapholz S. Germ-line transmission and expression of a human-derived yeast artificial chromosome. Nature Vol. 362, No. 6417, pp: 255-258 (1993); Jakobovits A, Vergara G, Kennedy J, Hales J, McGuinness R, Casentini-Borocz D, Brenner D, Otten G. Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production. Proceedings of the National Academy of Sciences USA Vol. 90, No. 6, pp: 2551-2555 (1993); Kucherlapati et al., U.S. Pat. No. 6,1075,181. [0019] Antibodies can also be made using phage display techniques. Such techniques can be used to isolate an initial antibody or to generate variants with altered specificity or avidity characteristics. Single chain Fv can also be used as is convenient. They can be made from vaccinated transgenic mice, if desired. Antibodies can be produced in cell culture, in phage, or in various animals, including but not limited to cows, rabbits, goats, mice, rats, hamsters, guinea pigs, sheep, dogs, cats, monkeys, chimpanzees, apes. [0020] Antibodies can be labeled with a detectable moiety such as a radioactive atom, a chromophore, a fluorophore, or the like. Such labeled antibodies can be used for diagnostic techniques, either in vivo, or in an isolated test sample. Antibodies can also be conjugated, for example, to a pharmaceutical agent, such as chemotherapeutic drug or a toxin. They can be linked to a cytokine, to a ligand, to another antibody. Suitable agents for coupling to antibodies to achieve an anti-tumor effect include cytokines, such as interleukin 2 (IL2) and Tumor Necrosis Factor (TNF); photosensitizers, for use in photodynamic therapy, including aluminum (III) phthalocyanine tetrasulfonate, hematoporphyrin, and phthalocyanine; radionuclides, such as iodine-131 (.sup.131I), yttrium-90 (.sup.90Y), bismuth-212 (.sup.212Bi), bismuth-213 (.sup.213Bi), technetium-99m (.sup.99mTc), rhenium-186 (.sup.186Re), and rhenium-188 (.sup.188Re); antibiotics, such as doxorubicin, adriamycin, daunorubicin, methotrexate, daunomycin, neocarzinostatin, and carboplatin; bacterial, plant, and other toxins, such as diphtheria toxin, pseudomonas exotoxin A, staphylococcal enterotoxin A, abrin-A toxin, ricin A (deglycosylated ricin A and native ricin A), TGF-alpha toxin, cytotoxin from chinese cobra (naja naja atra), and gelonin (a plant toxin); ribosome inactivating proteins from plants, bacteria and fungi, such as restrictocin (a ribosome inactivating protein produced by Aspergillus restrictus), saporin (a ribosome inactivating protein from Saponaria officinalis), and RNase; tyrosine kinase inhibitors; ly207702 (a difluorinated purine nucleoside); liposomes containing antitumor agents (e.g., antisense oligonucleotides, plasmids which encode for toxins, methotrexate, etc.); and other antibodies or antibody fragments, such as F(ab). Continue reading... Full patent description for Breast endothelial cell expression patterns Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Breast endothelial cell expression patterns patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Breast endothelial cell expression patterns or other areas of interest. ### Previous Patent Application: Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunoglobulin folds, bgs2, 3 and 4 and variants thereof Next Patent Application: Combination therapy Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Breast endothelial cell expression patterns patent info. IP-related news and info Results in 0.44441 seconds Other interesting Feshpatents.com categories: Software: Finance , AI , Databases , Development , Document , Navigation , Error |
||
